{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T05:01:21Z","timestamp":1780290081428,"version":"3.54.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Nowadays, the management of chronic obstructive airway diseases is shifting from traditional diagnostic labels toward a precision medicine approach based on \u201ctreatable traits.\u201d Among these, blood eosinophilia is emerging as a biomarker of type 2 (T2) inflammation across asthma and chronic obstructive airway diseases (COPD), even if its role as diagnostic tool and therapeutic target remains debated. In this manuscript we presented a clinical case of a 60-year-old male, former mild smoker (5 p\/y), initially diagnosed with severe COPD with persistent airflow limitation, frequent severe exacerbations and persistent eosinophilia, but a history of asthma and nasal polyposis. After six months with optimization of inhaled therapy and clinical reassessment, the diagnosis of \u201csevere COPD\u201d shifted to the diagnosis of \u201csevere eosinophilic asthma\u201d. Considering the new diagnosis, he was prescribed mepolizumab on top of triple inhaled therapy. After 1 year, the clinical response was excellent in terms of symptoms control, exacerbations reduction and OCS sparing, despite no improvement in lung function. Starting from this clinical case, the aim of this mini review is to describe the role of eosinophilic inflammation in asthma and COPD. While eosinophilic inflammation is a common feature of asthma, COPD is usually characterized by neutrophilic inflammation, even if, a subset of patients with COPD has eosinophilic inflammation. In this context, blood eosinophilia might represent a clinically actionable trait to guide diagnosis and personalized therapy in chronic airway diseases even if it should not be targeted in isolation but be integrated into a multidimensional assessment.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1868910","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:18:25Z","timestamp":1780287505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Is blood eosinophilia a treatable trait in chronic obstructive airway diseases?"],"prefix":"10.3389","volume":"17","author":[{"given":"Giulio","family":"Massetti","sequence":"first","affiliation":[{"name":"Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Martella","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ruini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Ruggieri","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia","place":["Modena, Italy"]},{"name":"Department of Life Sciences, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Beghe","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Section of Respiratory Diseases, University of Modena and Reggio Emilia","place":["Modena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"B1","unstructured":"GINA Strategy Report\n          \n          \n          \n          2025"},{"key":"B2","unstructured":"GOLD Report and Pocket Guide\n          \n          \n          \n          2026"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"Erj Open Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1900651","DOI":"10.1183\/13993003.00651-2019","article-title":"Airway inflammation in COPD: progress to precision medicine","volume":"54","author":"Brightling","year":"2019","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.01.011","article-title":"Treatable traits in airway disease: from theory to practice","volume":"11","author":"Agusti","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1802058","DOI":"10.1183\/13993003.02058-2018","article-title":"Treatable traits: a new paradigm for 21st century management of chronic airway diseases: treatable traits down under international workshop report","volume":"53","author":"McDonald","year":"2019","journal-title":"Eur Respir J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"230229","DOI":"10.1183\/20734735.0229-2023","article-title":"Type 2 inflammation in COPD: is it just asthma","volume":"20","author":"Beech","year":"2024","journal-title":"Breathe"},{"key":"B9","article-title":"Eosinophils and COPD","volume-title":"COPD in the 21st Century","author":"Beech","year":"2025"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1164\/rccm.202201-0209PP","article-title":"Blood eosinophils and chronic obstructive pulmonary disease: a global initiative for chronic obstructive lung disease science committee 2022 review","volume":"206","author":"Singh","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/copd.2006.1.1.39","article-title":"Eosinophilic airway inflammation in COPD","volume":"1","author":"Saha","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0302318","article-title":"High blood eosinophils predict the risk of COPD exacerbation: a systematic review and meta-analysis","volume":"19","author":"Chen","year":"2024","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s12931-020-01482-1","article-title":"Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00103","article-title":"Bidirectional mast cell\u2013eosinophil interactions in inflammatory disorders and cancer","volume":"4","author":"Galdiero","year":"2017","journal-title":"Front Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s40413-018-0192-5","article-title":"Type 2 immunity in asthma","volume":"11","author":"Caminati","year":"2018","journal-title":"World Allergy Organ J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12880","article-title":"Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications","volume":"47","author":"Robinson","year":"2017","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2024.05.011","article-title":"Towards precision medicine in COPD: targeting type 2 cytokines and alarmins","volume":"125","author":"Varricchi","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3MR1117-426R","article-title":"Eosinophil and airway nerve interactions in asthma","volume":"104","author":"Drake","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202407-1287RL","article-title":"Blood eosinophil count stability in chronic obstructive pulmonary disease and the eosinophilic exacerbator phenotype","volume":"211","author":"Baraldi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","article-title":"Blood eosinophil thresholds and exacerbations in chronic obstructive pulmonary disease","volume":"141","author":"Yun","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2401875","DOI":"10.1183\/13993003.01875-2024","article-title":"Transcriptomic profiling of the airway epithelium in COPD links airway eosinophilia to type 2 inflammation and corticosteroid response","volume":"65","author":"Leung","year":"2025","journal-title":"Eur Respir J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00174-2","article-title":"Eosinophils in asthma phenotypes: perpetrators or guilty by association","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12931-020-1279-4","article-title":"The stability of blood eosinophils in chronic obstructive pulmonary disease","volume":"21","author":"Long","year":"2020","journal-title":"Respir Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/15412555.2017.1313827","article-title":"Stability of blood eosinophil count in patients with COPD in the UK clinical practice research datalink","volume":"14","author":"Landis","year":"2017","journal-title":"Copd J Chronic Obstr Pulm Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1701162","DOI":"10.1183\/13993003.01162-2017","article-title":"Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD","volume":"50","author":"Casanova","year":"2017","journal-title":"Eur Respir J"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1800427","DOI":"10.1183\/13993003.00427-2018","article-title":"The reproducibility of COPD blood eosinophil counts","volume":"52","author":"Southworth","year":"2018","journal-title":"Eur Respir J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201701-0009LE","article-title":"Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts","volume":"195","author":"Oshagbemi","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S268018","article-title":"Blood eosinophil and risk of exacerbation in chronic obstructive pulmonary disease patients: a retrospective cohort analysis","volume":"15","author":"Chan","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201705-0973WS","article-title":"American thoracic society\/national heart, lung, and blood institute asthma\u2013chronic obstructive pulmonary disease overlap workshop report","volume":"196","author":"Woodruff","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210915","article-title":"ACO: time to move from the description of different phenotypes to the treatable traits","volume":"14","author":"Toledo-Pons","year":"2019","journal-title":"PloS One"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411532","article-title":"Lung-function trajectories leading to chronic obstructive pulmonary disease","volume":"373","author":"Lange","year":"2015","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S167600","article-title":"Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma\u2013COPD overlap","volume":"13","author":"Takayama","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12931-019-1138-3","article-title":"Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis","volume":"20","author":"Edris","year":"2019","journal-title":"Respir Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2000151","DOI":"10.1183\/13993003.00151-2020","article-title":"Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis","volume":"56","author":"Harrison","year":"2020","journal-title":"Eur Respir J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01597-9","article-title":"Real world effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/all.14135","article-title":"The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life","volume":"75","author":"Bagnasco","year":"2020","journal-title":"Allergy"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype","volume":"392","author":"Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1602486","DOI":"10.1183\/13993003.02486-2016","article-title":"A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis","volume":"49","author":"Dasgupta","year":"2017","journal-title":"Eur Respir J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/falgy.2022.881218","article-title":"Benralizumab in patients with severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: An ANANKE study post-hoc analysis","volume":"3","author":"D\u2019Amato","year":"2022","journal-title":"Front Allergy"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13103013","article-title":"Unlocking the long-term effectiveness of benralizumab in severe eosinophilic asthma: A three-year real-life study","volume":"13","author":"Pini","year":"2024","journal-title":"J Clin Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1172\/JCI95693","article-title":"Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction","volume":"128","author":"Dunican","year":"2018","journal-title":"J Clin Invest"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202110-2265OC","article-title":"Mucus plugs persist in asthma, and changes in mucus plugs associate with changes in airflow over time","volume":"205","author":"Tang","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: A conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2008.02971.x","article-title":"Pathogenesis of asthma","volume":"38","author":"Holgate","year":"2008","journal-title":"Clin Exp Allergy J Br Soc Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01196-2014","article-title":"Novel concepts in airway inflammation and remodelling in asthma","volume":"46","author":"Saglani","year":"2015","journal-title":"Eur Respir J"},{"key":"B71","doi-asserted-by":"publisher","first-page":"250024","DOI":"10.1183\/16000617.0024-2025","article-title":"Persistent airway obstruction in severe eosinophilic asthma: Targeting interleukin-5 and eosinophils","volume":"34","author":"Hanania","year":"2025","journal-title":"Eur Respir Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868910\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T04:18:26Z","timestamp":1780287506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1868910\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":71,"alternative-id":["10.3389\/fimmu.2026.1868910"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1868910","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"1868910"}}